Larvol Delta - Convergent-Therapeutics-Announces-Positive-Phase-2-Data-at-ASCO-2026-Showing-Promising-AntiTumor-Activity-Durability-and-Favorable-Tolerability-for-CONV01-in-LuPSMAExposed-Metastatic-CastrationResistant-Prostate-Cancer-mCRPC

Ac-225 rosopatamab tetraxetan (CONV01-α) - Convergent Therapeutics

https://www.businesswire.com/news/home/20260601939715/en/Convergent-Therapeutics-Announces-Positive-Phase-2-Data-at-ASCO-2026-Showing-Promising-Anti-Tumor-Activity-Durability-and-Favorable-Tolerability-for-CONV01--in-Lu-PSMA-Exposed-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC

Jun 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next